Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain.
The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.
The researchers found a perfect correlation between the AI-based multiparametric flow cytometry score and the IPSS-M.
Discrepancies between the WHO and ICC classification systems for MDS can create inconsistencies in a clinical setting.
Advertisement
Through genomic profiling, researchers identified 18 MDS subtypes associated with clinical outcomes.
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
Patients who received oral HMAs had half the mean total of health care encounter days as those who received IV or SC HMAs.
A TP53 variant allele frequency threshold of 24% can inform MDS prognosis equally as well as TP53 allelic status.
The IPSS-M significantly improved MDS prognostic assessment, particularly for high-risk IPSS-R cases.
In patients with lower-risk MDS receiving luspatercept, electronic medical record alerts can help improve treatment dosing.
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.
Luspatercept yielded high rates of durable transfusion independence in heavily-pretreated, lower-risk MDS.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.